Ro

Ro is a direct-to-consumer telehealth provider, which started by offering a telehealth platform for men's health. The company later broadened its scope and currently offers solutions for sexual health, weight loss, fertility, hair care, skin care, and daily health. The platform facilitates asynchronous care, where patients virtually consult with physicians, carry out at-home testing, and are issued prescription-grade medication. The company also operates a network of nationwide pharmacies and offers follow-up care services. Its pharmacies offer more than 500 generic medications via mail order

The company operates on both subscription and fee-per-service models. Ro charges users monthly subscriptions for deliveries of their required medication, coupled with specialist consultations, while offering OTC medication at a per-dose rate. As of July 2024, their subscriptions range from USD 14 per month to USD 144 per month based on the medication/treatment required. 

In November 2021, Ro announced its plans to acquire Dadi, an at-home men’s fertility kit provider, in order to bolster its expansion efforts in men’s and women’s health, particularly in the fertility tech space. The deal was completed in March 2022 and marked Ro’s fourth acquisition in the past 12 months, which included Workpath, Kit, and Modern Fertility. 

In May 2024, the company launched an interactive tool called the "GLP-1 Supply Tracker." The tool was free of charge for all users and was designed to offer patients timely information regarding GLP-1 drug availability in their local areas.

Key customers and partnerships

In December 2024, Ro partnered with pharmaceutical company Eli Lilly to expand distribution of single-dose vials of its GLP-1 weight loss medication Zepbound at reduced prices. The collaboration allowed Eli Lilly to reach Ro's established network of 1.5 million patients, while Ro gained the ability to offer FDA-approved Zepbound instead of solely relying on compounded versions of the medication.